-
Apellis Drug Becomes First Approved Therapy for Vision-Loss Disorder Geographic Atrophy
Apellis Drug Becomes First Approved Therapy for Vision-Loss Disorder Geographic Atrophy The FDA approved Apellis Pharmaceuticals’ Syfovre as a treatment for geographic atrophy, a retinal disorder that is a leading cause of blindness. The drug, administered as an injection into the eye, will launch in March at the price of $2,190 per vial. Information Courtesy…
-
STAT+: First non-immunosuppressive drug approved for a rare and deadly kidney disease
STAT+: First non-immunosuppressive drug approved for a rare and deadly kidney disease SAN DIEGO — Travere Therapeutics, a biotech focused both on treating rare diseases and distancing itself from controversial founder Martin Shkreli, on Friday won accelerated approval for a drug that treats IgA nephropathy, a rare and deadly autoimmune disease that attacks the kidneys…
-
STAT+: FDA approves first treatment for leading cause of blindness in older people
STAT+: FDA approves first treatment for leading cause of blindness in older people The Food and Drug Administration approved on Friday the first treatment for geographic atrophy, a progressive eye disease and a leading cause of blindness in older people. The new drug, called Syfovre, is made by Apellis Pharmaceuticals. Continue to STAT+ to read…
-
Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency
Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency Chiesi drug Lamzede is an engineered version of an enzyme that’s lacking in patients with the rare disease alpha-mannosidosis. FDA approval of the Chiesi drug comes about five years after European regulators authorized the product. Information Courtesy By: Frank Vinluan, #HealthcareNews #Healthcare |…
-
STAT+: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn
STAT+: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn In the aftermath of the Food and Drug Administration’s Aduhelm debacle, the agency’s neuroscience chief Billy Dunn has another controversial approval decision to make. It will once again test his willingness to apply the FDA’s doctrine of “regulatory flexibility”…
-
FDA advisers recommend approval of over-the-counter naloxone to fight opioid overdose
FDA advisers recommend approval of over-the-counter naloxone to fight opioid overdose A government advisory committee voted unanimously on Wednesday to recommend that naloxone nasal spray, a medication used to reverse opioid overdoses, be sold and distributed without a prescription. The vote serves as a recommendation to the Food and Drug Administration as the agency considers…
-
Healthcare Moves: A Monthly Summary of Executive Appointments and Layoff News
Healthcare Moves: A Monthly Summary of Executive Appointments and Layoff News Here is a selection of recent executive hires, departures and layoffs occurring across the healthcare industry. Information Courtesy By: Katie Adams, #HealthcareNews #Healthcare | Feeds Here is a selection of recent executive hires, departures and layoffs occurring across the healthcare industry. Click For More…
Got any book recommendations?